Commissioner McClellan Visits Mass Bio: Phase IV, Orphan Drugs On Agenda

Phase IV commitments should be discussed earlier in the review process to improve the cost-effectiveness of drug development, the Massachusetts Biotechnology Council told FDA Commissioner McClellan

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet